DMN:FRA
Diamyd Medical AB
€0.064
arrow_upward
+1.92%(+0.0012) 1D
Nov 20, 8:04:51 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
135.11M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
135.11M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
News stories
From web sources and news partners
marketscreener.com
·
1 hour ago
Societe Generale sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
41 minutes ago
Mohamed A. El-Erian: S&P 500 may face longest losing streak since 2020 as 10-year Treasury yield falls
Barron's
·
1 hour ago
S&P 500 Futures Decline in Premarket Trading; Lennar, Louisiana-Pacific Lag
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees42
Founded1984
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitediamyd.com